News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
490,849 Results
Type
Article (30391)
Company Profile (176)
Press Release (460282)
Section
Business (141461)
Career Advice (615)
Deals (23629)
Drug Delivery (63)
Drug Development (55969)
Employer Resources (84)
FDA (13891)
Job Trends (11496)
News (240570)
Policy (23340)
Tag
Academia (2113)
Alliances (37771)
Alzheimer's disease (963)
Approvals (13894)
Artificial intelligence (152)
Bankruptcy (166)
Best Places to Work (9567)
Biotechnology (115)
Breast cancer (169)
Cancer (1234)
Cardiovascular disease (104)
Career advice (553)
Cell therapy (227)
Clinical research (46413)
Collaboration (504)
Compensation (125)
COVID-19 (1746)
C-suite (128)
Data (1242)
Diabetes (146)
Diagnostics (4748)
Earnings (49965)
Events (71258)
Executive appointments (425)
FDA (14607)
Funding (424)
Gene therapy (140)
GLP-1 (452)
Government (3471)
Healthcare (15295)
Infectious disease (1820)
Inflammatory bowel disease (90)
IPO (10238)
Job creations (2344)
Job search strategy (502)
Layoffs (227)
Legal (4566)
Lung cancer (190)
Lymphoma (81)
Manufacturing (163)
Medical device (13659)
Medtech (13663)
Mergers & acquisitions (13660)
Metabolic disorders (369)
Neuroscience (1232)
NextGen: Class of 2025 (5091)
Non-profit (3723)
Northern California (1317)
Obesity (208)
Opinion (118)
Parkinson's disease (87)
Patents (102)
People (44148)
Phase I (13820)
Phase II (20105)
Phase III (16101)
Pipeline (460)
Postmarket research (1817)
Preclinical (4667)
Radiopharmaceuticals (225)
Rare diseases (189)
Real estate (4221)
Regulatory (16563)
Research institute (1979)
Southern California (1157)
Startups (2822)
United States (12781)
Vaccines (387)
Weight loss (138)
Date
Last 7 days (537)
Last 30 days (1510)
Last 365 days (27462)
2025 (1282)
2024 (27745)
2023 (30940)
2022 (40031)
2021 (43091)
2020 (41935)
2019 (37853)
2018 (28799)
2017 (25081)
2016 (24042)
2015 (27693)
2014 (20575)
2013 (16850)
2012 (18380)
2011 (18571)
2010 (16720)
Location
Africa (465)
Arizona (127)
Asia (30962)
Australia (4843)
California (3014)
Canada (1260)
China (332)
Colorado (151)
Connecticut (180)
Delaware (86)
Europe (66392)
Florida (488)
Georgia (130)
Illinois (367)
Indiana (228)
Japan (80)
Maryland (625)
Massachusetts (2349)
Michigan (128)
Minnesota (272)
New Jersey (1011)
New York (941)
North Carolina (612)
Northern California (1317)
Ohio (137)
Pennsylvania (795)
South America (697)
Southern California (1157)
Texas (488)
Utah (94)
Washington State (255)
490,849 Results for "410 medical innovation".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Startups
Verdiva Jumps Into Hot Obesity Market With $410M Debut, Eyes Next-Gen Therapies
The company’s lead asset is a potentially first-in-class oral GLP-1 receptor agonist that has the potential to be dosed weekly, which according to CEO Khurem Farooq can help improve accessibility and affordability.
January 9, 2025
·
2 min read
·
Tristan Manalac
Press Releases
Verdiva Bio, a New Clinical-Stage Cardiometabolic Company, Launches with Over $410M in Series A Financing to Advance Next-Generation Therapies
January 9, 2025
·
5 min read
Press Releases
In-Vitro Diagnostics Enzymes Market Size to Surpass USD 4.10 Bn by 2033
November 19, 2024
·
1 min read
Drug Development
NextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024
NextCure, Inc. today announced that clinical data from the Phase 1b portion of a Phase 1b/2 study evaluating NC410, a LAIR-2 fusion protein, in combination with pembrolizumab will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
May 30, 2024
·
5 min read
Press Releases
Data and Safety Monitoring Board Reviews Interim Safety Data of Phase 2 Subjects of OCU410 ArMaDa Clinical Trial for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
December 19, 2024
·
6 min read
Drug Development
Data and Safety Monitoring Board Approves Simultaneous Enrollment in Cohort 3 and Phase 2 Initiation in OCU410 ArMaDa study for Geographic Atrophy
Ocugen, Inc. announced a positive outcome of the Data and Safety Monitoring Board Review for its Phase 1/2 ArMaDa clinical trial for OCU410 —a modifier gene therapy candidate being developed for geographic atrophy, an advanced stage of dry age-related macular degeneration.
May 31, 2024
·
5 min read
Pharm Country
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
Ocugen, Inc. announced that the Data Safety and Monitoring Board for the OCU410ST clinical trial recently convened and approved to proceed dosing with the medium dose of OCU410ST in the dose-escalation phase of the study.
April 1, 2024
·
4 min read
Press Releases
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease
October 23, 2024
·
5 min read
Drug Development
Ocugen Announces Dosing Completion of Subjects with Geographic Atrophy in Cohort 2 of Phase 1/2 ArMaDa Clinical Trial of OCU410—A Modifier Gene Therapy
Ocugen, Inc. today announced that dosing is complete in the second cohort of its Phase 1/2 ArMaDa clinical trial for OCU410 (AAV- hRORA ).
April 19, 2024
·
5 min read
Drug Development
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
Ocugen, Inc. announced that the Data and Safety Monitoring Board for the Phase 1/2 ArMaDa clinical trial for OCU410 recently convened and approved to proceed dosing with the medium dose of OCU410 in the dose-escalation phase of the study.
April 5, 2024
·
4 min read
1 of 49,085
Next
